The Supreme Court has temporarily blocked restrictions on the abortion pill mifepristone that would have disrupted access to medication used by more than 60% of abortion patients nationwide, issuing a one-week delay as the drug remains available through telehealth and mail delivery until at least May 11.
Supreme Court Justice Samuel Alito issued an order Monday temporarily pausing an appeals court decision that would have required in-person doctor's visits for mifepristone nationwide. The ruling on hold is from the 5th Circuit, based in New Orleans, which said mifepristone could not be mailed anywhere in the country, creating what Julie Rovner described as "mass confusion" given that the medication is also used to treat miscarriage.
The Human Impact of Restrictions
Medication abortion now makes up some two-thirds of all U.S. abortions, according to CNN, meaning any restrictions would fundamentally reshape reproductive healthcare access for millions of women. Rovner noted that telehealth has allowed women to get around most state bans in the 20 states that now have them, making the court battles over mailing and online prescribing critical to maintaining access.
Louisiana brought the case against the Food and Drug Administration, arguing that access to medication abortion should be restricted. The state has been asked to file briefs on Thursday as the court considers whether to keep the status quo, allow the appeals court ruling to take effect, or pursue another option entirely.
A Decades-Old Approval Under Attack
The legal challenges extend beyond current regulations. Rovner said a 2023 case out of Texas asked not only to roll back availability to what it was prior to 2021, when patients physically had to get the pill handed to them by a doctor, but also to cancel the pill's FDA approval altogether. She said the original approval goes back more than a quarter of a century to when Bill Clinton was president.
The Supreme Court in 2024 rejected a challenge to the pill's access brought by anti-abortion doctors because the physicians had not shown they were being harmed by the current regulations in a way that would warrant court intervention. Rovner said the earlier case was dismissed because the doctors group that brought it lacked standing to sue, but noted the Louisiana case is less likely to face that problem.
Political Pressure and Administrative Response
The Trump administration itself had asked the lower court to put the case on hold until the FDA finishes an ongoing review of mifepristone's safety, which Rovner said would not happen until much later this year. However, court briefs from Louisiana noted how a Justice Department lawyer could promise only that parts of the review "might" be done by 2027.
CNN quoted Kelsey Pritchard of Susan B. Anthony Pro-Life America as saying, "What is shocking is that the Trump administration's inaction has stopped pro-life laws from taking effect, and that they forced several Republican attorneys general to take their battle to the federal courts." Pritchard also said, "It's just really hard for us to understand how the Trump administration has been so negligent as to leave this policy in place."
Anti-abortion advocates have grown to suspect the FDA review is a way to slow-walk the issue, a claim the FDA has previously denied. A Wall Street Journal report indicated Marty Makary had expressed indifference to regulations for mifepristone.
Electoral Implications
Rovner said the issue affects the political landscape ahead of the midterms and that anti-abortion groups have been increasingly vocal about their frustration that the president has not done more to limit, if not outlaw, the abortion pill. She said President Trump has said several times he does not want to impose more restrictions on abortion because most voters support abortion rights, even in many red states, and that abortion is likely to be front and center in this year's elections.
CNN said the return of abortion to the Supreme Court is testing President Donald Trump's strategy of avoiding the issue. Sam Bagenstos, who was general counsel for US Department of Health and Human Services during the Biden administration, told CNN, "It's clear that they do not want to have a ruling taking access to mifepristone away from women across the country before the midterms," adding, "However, they are doing everything they can to preserve their ability to take access to mifepristone away from women across the country as soon as they're out of the woods."
The Democratic National Committee accused Trump in a statement Monday of making "it even harder to get lifesaving reproductive healthcare by banning medication that has been safely used for decades."
Mary Ziegler, a law professor at University of California, Davis, told CNN, "As this case moves along, the current game plan about making this only about procedural issues is going to become more and more untenable," and, "The 5th Circuit blew up that strategy."
Bagenstos, now a University of Michigan Law School professor, said the Trump administration is eventually "going to have to put up or shut up about their position regarding whether mifepristone was appropriately approved for termination of pregnancy and whether the in-person dispensing requirement should have been eliminated," adding, "Are they going to have to do that soon? You know, it all depends on what the Supreme Court does."
Why This Matters:
Access to mifepristone directly affects healthcare options for millions of women across the country, particularly those in the 20 states with abortion bans who have relied on telehealth to maintain reproductive autonomy. The medication accounts for more than 60% of all abortions and is also essential for miscarriage treatment, meaning restrictions would fundamentally reshape women's healthcare access regardless of pregnancy intentions. The legal battle threatens to eliminate a FDA-approved medication that has been safely used for more than a quarter of a century, potentially setting a precedent for political interference in medical regulatory decisions. With the Supreme Court's temporary hold expiring May 11 and parties having just days to deliver arguments, women nationwide face uncertainty about whether they will retain access to essential reproductive healthcare. The political timing ahead of midterm elections underscores how reproductive rights continue to mobilize voters, with polling showing majority support for abortion access even in conservative states, creating tension between electoral realities and anti-abortion advocacy demands.